Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Denosumab[1] Denosumab[1] Denosumab 💬[1] TNFSF11 💬[8] Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬[8] 46, 50, 70, 93, 95, 96, 274, 299 💬
2Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand[1] Denosumab[1] Denosumab 💬[1] TNFSF11 💬[8] Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬[1] 274 💬
3Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand[1] Denosumab[1] Denosumab 💬[1] TNFSF11 💬[8] Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬[1] 274 💬
4PRALIA 60 mg Subcutaneous Injection Syringe(denosumab)[1] Denosumab[1] Denosumab 💬[1] TNFSF11 💬[8] Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬[1] 46 💬
5PRALIA 60mg Subcutaneous Injection Syringe(denosumab)[1] Denosumab[1] Denosumab 💬[1] TNFSF11 💬[8] Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬[1] 46 💬